WSGR logoWSGR logo
Daria Lukasz
Patent Agent
Patents and Innovations
Washington, D.C.

D202-973-8858

Download vCard
Open PDF

Dr. Daria Lukasz is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her background includes extensive knowledge in the biomedical sciences, particularly cellular and molecular biology, genetics, neuroscience, and developmental biology.

Prior to joining the firm, Daria completed her doctoral training at the National Institutes of Health in Bethesda, MD, under the guidance of Dr. Katie Kindt. As a graduate student in the NIH-Johns Hopkins University Graduate Partnerships Program, she used a combination of genetics, pharmacology, electrophysiology, and in vivo cell biology assays to study sources of metabolic stress in auditory and vestibular hair cells in a zebrafish model of deafness. 

Experience

Dr. Daria Lukasz is a patent agent in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her background includes extensive knowledge in the biomedical sciences, particularly cellular and molecular biology, genetics, neuroscience, and developmental biology.

Prior to joining the firm, Daria completed her doctoral training at the National Institutes of Health in Bethesda, MD, under the guidance of Dr. Katie Kindt. As a graduate student in the NIH-Johns Hopkins University Graduate Partnerships Program, she used a combination of genetics, pharmacology, electrophysiology, and in vivo cell biology assays to study sources of metabolic stress in auditory and vestibular hair cells in a zebrafish model of deafness. 

Focus Areas
Recent Insights
Alerts
The Inflation Reduction Act’s Medicare Price Negotiation Program: Two Years Later
The Inflation Reduction Act (the Act) of 2022 was controversial at the time the Act was signed into law and remains so. To date, multiple legal challenges have been asserted against the Act, with more expected in the future.
Learn More
Client Highlights
Wilson Sonsini Advises Metagenomi on IP Matters Related to $93 Million IPO
On February 13, 2024, Metagenomi, Inc., a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. The shares began trading on the Nasdaq Global Select Market on February 9, 2024, under the ticker symbol “MGX.” The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.
Learn More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.